TP73 and prostate cancer: Furthermore, TP73 overexpression has been reported in several tumor types, including breast cancer, melanoma, prostate cancer and neuroblastoma, and was shown to induce metastasis, chemo-resistance and other hallmarks of tumor progression that confer poor clinical outcome [27].